Latest filing published 28 Sept 2023 for Sangamo Therapeutics, INC, €2.8M.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Biogen Inc.: trading record in brief
This profile gathers the share dealings of Biogen Inc. across 2 companies, led by Sangamo Therapeutics, Inc and Bioverativ Inc. The record holds 13 filings, for trades running from 1 February 2017 to 26 September 2023.
Sales make up the whole of the open-market record (12 sales, €7.5M). Since January 2023: no purchases and 1 sale on the market.
The newest entry dates from 28 September 2023: an open-market sale of €2.8M, in Sangamo Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Biogen Inc.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 6,000,000 shares@ US$0.5036.2% of flowCommon StockSEC:0000899243-23-019611:0
- 400,000 shares@ US$5.326827.2% of flowCommon StockSEC:0000899243-22-030136:0
- 2,764 shares@ US$8.51010.3% of flowCommon StockSEC:0000875045-21-000061:0
- 81,187 shares@ US$8.55479.6% of flowCommon StockSEC:0000875045-21-000060:0
- 23,660 shares@ US$8.56052.8% of flowCommon StockSEC:0000875045-21-000059:0
- 52,178 shares@ US$8.51776.2% of flowCommon StockSEC:0000875045-21-000058:0
- 730 shares@ US$8.52490.1% of flowCommon StockSEC:0000875045-21-000057:0
- 28,884 shares@ US$8.60113.5% of flowCommon StockSEC:0000875045-21-000055:0
8 of 8 declarations
